Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
+$0.09 today
- Market cap
- $1.93B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
Volume 1.05M
Average 1.18M
Returns on capital
Vera Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-49.6%
avg -34.4%
ROIC
-46.3%
avg -89.8%
ROA
-40.8%
avg -77.7%
Analysis
ROA is currently the strongest return metric at -40.8% versus its period average of -77.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Marshall Fordyce | Founder, President, Chief Executive Officer & Director | USD 1.21M | 51 | 235.24K | 0.33% |
David L. Johnson | Chief Opearating Officer | USD 798.6K | 56 | — | — |
Robert Brenner | Chief Medical Officer | USD 797.04K | 58 | 50.95K | 0.07% |
Sean Grant | Chief Financial Officer | USD 793.92K | 41 | 114.18K | 0.16% |
Jane Wright-Mitchell | Chief Legal Officer & Secretary | — | 57 | 0 | <0.01% |
Tom Doan | Executive Vice President of Development Operations | — | 54 | — | — |
Debra Charlesworth | Vice President of Corporate Communications | — | — | — | — |
Emma Haywood | Vice President of Marketing | — | — | — | — |
S. Sandra Park | Senior Vice President of Legal, Healthcare,Commercial Law, Compliance & Operations | — | — | — | — |
Joseph R. Young | Senior Vice President of Finance & Chief Accounting Officer | — | 54 | 33.59K | 0.05% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 15, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$249,985.00
Sells
32
$11.89M
Net Transaction Value
−$11.64M
Net selling
Most Active
Fordyce Marshall
22 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 15, 26Sep 15, 2026 | Fordyce Marshall Direct | Sell | $684.5K$684,500.00 |
| Sep 2, 26Sep 2, 2026 | Fordyce Marshall Direct | Sell | $649.6K$649,642.30 |
| Jul 7, 26Jul 7, 2026 | Fordyce Marshall Direct | Sell | $450K$450,006.90 |
| Jul 7, 26Jul 7, 2026 | Fordyce Marshall Direct | Sell | $40.8K$40,776.20 |
| Jul 7, 26Jul 7, 2026 | Fordyce Marshall Direct | Sell | $1.4M$1,369,495.68 |
| Jul 7, 26Jul 7, 2026 | Fordyce Marshall Direct | Sell | $450K$450,006.90 |
| Jul 7, 26Jul 7, 2026 | Fordyce Marshall Direct | Sell | $95.9K$95,908.34 |
| Jul 7, 26Jul 7, 2026 | Fordyce Marshall Direct | Sell | $40.8K$40,776.20 |
| Jul 7, 26Jul 7, 2026 | Fordyce Marshall Direct | Sell | $1.4M$1,369,495.68 |
| Jul 7, 26Jul 7, 2026 | Fordyce Marshall Direct | Sell | $95.9K$95,908.34 |
1–10 of 33
Summary
Insiders reported 1 buys worth $249,985.00 and 32 sells worth $11.89M over the last 12 months. That adds up to net selling of $11.64M. Fordyce Marshall was the most active insider with 22 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Vera Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about VERA's management, answered from reported figures.
Who manages VERA?
Vera Therapeutics, Inc. (VERA) lists 10 active executives. The top listed executive is Jane Wright-Mitchell, Chief Legal Officer & Secretary.
Are VERA insiders buying or selling?
Recent insider activity shows net buying of $32.43M.
Continue the stock analysis
Jump to another research area for this company.